Terms: = Gastric cancer AND FUBP1, FBP, 8880, ENSG00000162613, FUBP AND Clinical Outcome
1 results:
1. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and fubp1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract] [Full Text] [Related]
